Pharmaceutical industry
Every story that matters from the perspective of the pharmaceutical industry, with one sentence on what it means for them specifically. 131 stories, latest first.
November 2026
SK Biopharmaceuticals builds large AI dataset for drug discovery as GaiaBT ties AI to lab validationBuilding proprietary datasets and lab validation are the two decisive elements of AI research.Roche partners with Chai Discovery to deploy Chai-3 model across its pipelinesAnother example of large companies integrating external AI molecule-design platforms into their in-house pipelines.ChemLex raises $45M and launches self-driving lab for drug discovery in SingaporeAutomated, AI-driven experimental labs may become available as a service.Study of 3,011 FDA warning letters finds seven citing AI, including earliest CDER letterThe use of AI in manufacturing must be documented and validated within the quality assurance system, as the regulator already refers to it.Agilent completes Proscia acquisition for up to $270mAI-based pathology data is playing a growing role in companion diagnostics development.AI-generated fake ads misuse names of Semmelweis University and BENU pharmacy chainThe names of pharmacies and pharmaceutical retailers can be used in fake ads, so brand protection and public information need to be strengthened.Drugmaker CEOs doubt AI's promise to cure disease as Sanofi halts a Nurix-partnered programAI-derived candidates must show clinical evidence; promises do not automatically turn into pipeline value.Microsoft's MAI-DxO diagnostic AI agent diagnoses more than twice as accurately as doctorsMedical AI agents may reshape diagnostic careers and costs.Google's AI agent can propose new drug molecules within hours, DeepMind saysAgent-based cheminformatics could shorten the time it takes to propose molecules in early-stage research.QUANTRO wins Austrian FFG grant to build AI drug discovery platformA Central European AI drug discovery effort receives public funding.Isomorphic Labs in talks to raise about $5 billion for AI drug discoveryThe fundraising could intensify competition among AI-native players for partnerships and talent, and the first human trials will serve as a benchmark.Anthropic expands into life sciences: Johns Hopkins technology, drug discovery and clinical trial designAI support for trial design, document review and molecule search may speed up development steps, but it must be validated.nPhase raises $30M Series D for AI-native clinical data platformData management and statistical processing in clinical trials could be automated with AI agents.
Oct 2026
Isomorphic Labs plans human trials soon of AI-designed cancer drugsClinical data from the first AI-designed oncology candidates will be an important signal for partnership and licensing decisions.Flagship merges three biotech platforms into AI drug discovery company EtceleraAnother AI-native player is entering the partnering and acquisition market.Formation Bio launches $600 million fund to buy clinical-stage drug candidatesClinical trial capacity and the price of phase I–II candidates may rise in value, and exit options for smaller developers may improve.Beijing-based BioGeometry raises more than $100M for AI drug discoveryCapital flowing to Chinese AI drug-discovery companies is also expanding the licensing and partnering market.Anthropic enters drug development with an acquisition, six industry partners and an IPO filingTarget identification and experiment design could speed up (Mithril's founder estimates days instead of the previous 1–2 months), so a partnership or procurement decision is worth considering.Pharma and AI firms sign $3.8 billion in deals in one monthAI partnerships have become a standard business model; pipeline strategy must decide the balance between in-house and external AI capability.Insilico's AI-designed cancer drug shows 40% response rate in mesotheliomaClinical efficacy data on AI-designed molecules serve as evidence when assessing AI-driven pipelines.AstraZeneca turns to Oracle for AI-driven clinical trial enrolmentRecruitment time is one of the main bottlenecks in trials, so this solution may also affect site selection and scheduling.AstraZeneca and Oracle to build AI platform for clinical trial recruitment and safety monitoringAI recruitment based on real-world patient data could shorten trial start-up times and serve as a model for redesigning trial processes.OpenAI acquires Orchestra Bio, entering drug developmentLarge AI companies are entering the market for drug-development agent platforms directly, creating both partnership and competition.Radical Numerics says first AI-designed phage therapy has reached a human patientThe first use of an AI-designed biological therapy in a human raises new regulatory and manufacturing questions.Abu Dhabi health department signs agreements and publishes AI clinician frameworkThe AI drug discovery agreements open up new collaboration opportunities in the Gulf region.Richter Gedeon discusses validated use of AI and advanced process control in pharmaceutical manufacturingDomestic manufacturers are examining AI in process control built into validated production environments, which requires compliance planning.Lilly, Astellas, Novo Nordisk and BMS strike further AI drug discovery dealsLarge pharma companies treat milestone-based deals with external AI platforms as part of their R&D strategy.AI in pathology and dermatology: lung cancer biomarkers, Lunit–Summit, Mayo ClinicAI pathology may also play a role in selecting patients for trials and in drug development.Anthropic, Google, ByteDance and Tencent turn to AI drug discovery; Citrini tests ClaudeThe entry of technology companies calls for rethinking research partners and supply-chain dependencies.Isomorphic Labs raises $2.1 billion; Warp Sciences launches with $215 million; Reflector Bio emerges from stealthCapital for AI-first biotech companies is growing, which means both partnership opportunities and competition.Pharma industry bets on AI to cut costs and timelines; scaling beyond pilotsWhen scaling AI pilots, data readiness should be scored together with business value.AI-generated evidence in drug discovery: reliability, legal risk and FDA complianceAI-generated citations and results must be handled with documented verification before they enter submission materials.Utah approves AI system that prescribes medication without physician oversightDirect AI prescribing could also change the access path for prescription-only products.AstraZeneca signs $40 million AI drug discovery deal with insitro for cardiometabolic diseasesAnother large drugmaker is forming a development partnership with an external AI platform provider, a benchmark for collaboration models.Budapest panel asks what holds back AI adoption in pharma: technology, culture or regulationHungarian players see organisational and regulatory barriers as obstacles to AI adoption.MHRA sets out how medicines regulation will adapt to the era of AIIn marketing authorisation submissions, it is worth aligning the documentation of AI use with MHRA expectations.Iambic raises $150M in IPOThe market reception signals investor appetite for AI-based drug developers, which may also affect partnership negotiations.Zealand Pharma and Generate Biomedicines sign $1.2 billion AI agreementAI-driven protein design in obesity and metabolic diseases could also speed up partner searches by competitors.Insilico's Pharma.AI fall 2026 release adds specialized models and AI agentsThe platform update points toward agent-based workflows and is worth comparing with companies' existing tool stacks.GSK expands AI drug discovery collaboration with Chai DiscoveryThe expansion after the laboratory evaluation signals that protein design models may enter the research workflow.Agilent to acquire digital pathology firm Proscia for up to $270MBiopharma research may also gain access to digital pathology capabilities.Trial sponsors say AI speeds timelines, but validation and governance lagValidation and governance processes for AI use in trials need strengthening before further rollout.India's TDB backs Peptris with ₹86 crore for AI-driven drug developmentIf Indian AI-based candidates reach clinical phases, it could show how much cheaper discovery is actually worth.Chinese AI-discovered drug candidates reach regulatory and development milestonesAI-discovered candidates from Chinese companies are already entering the stage of clinical trial authorisation.OpenAI quietly posts unpublished life sciences model gpt-rosalind-discoveryIt is worth examining how the model compares with research tools already in use and with data protection requirements.Analysis: AI-enabled drug discovery pipeline is growing but remains largely early-stageThe early-stage nature of the pipeline warrants cautious expectations about the success rates AI promises.AI companies run virtual drug trials to improve success of human studiesVirtual trials target pre-clinical screening and lower dropout rates, so it is timely to assess the providers.Charm doses first patient with AI-designed menin inhibitorAI-designed molecules entering clinical phases are the first real test of how effective AI-driven research is.Danaher launches AI-powered autonomous drug discovery lab; Carterra announces new collaborationAutomated, AI-in-the-loop labs aim to speed up the research cycle, so supplier offerings are worth watching.AI in regulatory filings and trials: Annovis partners with Weave Bio; Cori Clinical raises $4M seed roundAI has also appeared in preparing regulatory documentation and organising trials.Isomorphic Labs reportedly seeking funding at $40–50 billion valuationHuge valuations for AI-native drug developers could redraw the partnership and competitive landscape.HHS and ARPA-H move to speed up clinical trials with AIImprovements to federal trial infrastructure affect opportunities in trial organisation and data collection.Virtual biotech staffed by 37,000 AI agents finds marker for more successful medicinesThe agent-based research model points to a new methodological direction in candidate selection.Four ARPA-H initiatives aim to modernize US clinical trialsAI-driven modernization of trial processes could change development timelines.How does an AI pathology tool become a companion diagnostic?For companion-diagnostic AI, the path from research use to clinical access requires accreditation.
September 2026
EU AI Act in healthcare: high-risk rules and deadlines in 2027 and 2028Should assess which of its internal AI tools fall into the high-risk category.Tremont AI emerges from stealth with AI platform for preclinical drug safetyAI-based safety prediction can be built into the preclinical toxicology workflow.AI drug discovery tools carry risky contract terms as USPTO inventorship rules changeAI vendor contracts and the handling of inventorship rights must undergo legal review.AbbVie partners with IPO-bound Iambic as Insilico picks another AI-designed obesity drug candidateAI-led research partnerships and AI-designed candidates are also appearing in large companies' portfolios.Health AI lab launches with $500M backing; OpenEvidence raises $250MThe new, well-capitalized players in drug-development AI may become competitors or partners.Independent analysis: Medable's AI agent saves millions in clinical trial costsMonitoring trials with an AI agent could bring cost and time savings.Roche plans move towards autonomous AI-driven laboratories in drug developmentLinking laboratory automation with AI-based design could become a competitive factor.New rules for AI-generated real-world evidence in Canadian health technology assessmentsAI-generated RWE in Canadian HTA submissions must be submitted under the new rules.AI analysis reveals little-known side effects of GLP-1 analoguesAI-based drug-safety analysis may affect pharmacovigilance processes.Enveda raises $311m and Basecamp Research $140m for AI drug discoveryThe inflow of capital supports AI biotechs' move into the clinical stage, so competitor monitoring should track these candidates too.Insilico doses first patient in Phase III trial of AI-designed lung disease drugAn AI-designed molecule reaching Phase III sets a benchmark for expectations on efficacy and timelines.AbbVie forms AI drug discovery partnership with Iambic, which is preparing a stock market listingBig pharma partnerships with AI biotechs reinforce the pattern of outsourcing early-stage research, so companies should review their own partnership strategy.New pharma–AI partnerships: Novo Nordisk–Anthropic, Lilly–Twist, Boehringer Ingelheim–EnvisagenicsContracts with AI companies are multiplying quickly, so it is worth setting terms for target identification and data sharing proactively.India's drug regulator forms AI expert committeeIn Indian clinical trial decisions, expert committee review still counts and AI does not replace it.Anthropic sets up a biology lab, says it is not specifically for drug researchAn AI developer is building its own laboratory, which could reshape the division of labour between model providers and pharmaceutical companies.Virtual biotech puts up to 37,000 AI agents to work on drug discovery, with lung cancer candidateThe multi-agent framework points to automation of target identification and development planning, which makes pilot testing of research workflows worthwhile.Novo Nordisk to use Anthropic's Claude in drug researchA major drugmaker is publicly building its research on a large language model, which gives competitors a benchmark for their own AI strategies.GenScript and Twist join Eli Lilly's TuneLab AI platformUnder the TuneLab model, contract partners supplying experimental data become integral parts of AI platforms, which matters when selecting CRO partners.ByteDance AI drug discovery unit Anew Labs raises $290M at $1.5B valuationA technology giant's spun-off AI unit is entering drug discovery with substantial capital, a matter for partnership planning and competitor monitoring.FDA weighs changes to clinical trial design, drug development and use of AI in trialsChanges to trial-design and AI-use rules may affect development plans, so they are worth tracking.Insilico launches AI-driven longevity vaccine research for age-related diseasesA new therapeutic area opens for AI researchers, but the programme is at an early stage.Virtual cell model predicts effective drug for triple-negative breast cancerCell-model-based prediction can support candidate selection and trial design.AI and personalised medicines on the agenda at Bosch and Richter conferenceA leading player in Hungary's pharmaceutical industry is discussing the link between AI and personalised therapies at a public professional forum.Drug firms' proprietary data boost AI protein modelsProprietary data is a competitive advantage in model training, so data-sharing and federated learning collaborations are worth considering.Insilico's AI-discovered drug rentosertib enters phase 3 in idiopathic pulmonary fibrosisOne of the most closely studied AI-discovered molecules has reached the pivotal stage, which may serve as a benchmark for evaluating AI-derived pipelines.Moderna and Merck's AI-built cancer vaccine clears phase 3, PYMNTS reportsIn personalised mRNA therapy development, the role of AI may be validated at the pivotal stage, so platform strategy deserves reassessment.Is AI accelerating drug discovery? Two-molecule data and a JCIM analysisThe findings offer a critical benchmark for internally validating AI promises in lead optimisation.AI in life sciences: ten legal considerations for drug discoveryThe legal risks of AI use should be addressed in internal compliance checks.QP training: AI in pharmaceutical quality assurance, with speaker from Hungary's public health centreQuality assurance professionals can learn regulator-side considerations on applying AI.Lunit and 10x Genomics to link AI pathology with spatial molecular dataIntegrated imaging and molecular analysis can speed up biomarker research in oncology studies.Novo Nordisk and AWS form strategic partnership to accelerate AI-driven drug discoveryLarge companies are building R&D on cloud AI platforms, which affects supplier and data-management decisions.Pharmahungary Group develops microRNA therapy with artificial intelligenceA Hungarian company is bringing AI into microRNA-based therapy development.AI-discovered rentosertib lowered biological age on six aging clocks in lung disease trialUsing aging clocks as secondary endpoints is a new trial-design option, but it needs validation.Hungary plans HUF 35 billion to develop its health and life sciences AI sectorBecause of the life sciences focus, funding of AI-based R&D collaborations is also affected.Insilico's rentosertib enters Phase III trialThis is the first major test of whether an AI-discovered molecule can also succeed in the pivotal phase.nPhase, IQVIA and others rebuild clinical development around AI, data foundations and agentsPutting trial data foundations and governance in order is a prerequisite for adopting AI.AI drug discovery hits a new bottleneck: experimental validationExperimental validation capacity must be planned together with AI candidate generation.Owkin signs AI drug discovery deal with Boehringer Ingelheim for cancer and immunologyThe collaboration model shows that large companies are expanding their research pipelines with external AI platforms.Insilico Medicine releases frontier AI models for drug discoveryResearch teams should evaluate the new models against their own target and molecule identification workflows.Weave Bio and Takeda deploy AI regulatory automation across 14 global programsAI automation of regulatory submission documents can speed up regulatory workflows, so a pilot is worth starting.
August 2026
New AI drug discovery tie-ups and projects: Ono–Aitia, Hiro, MND, JapanFoldThe partnerships and local data-handling arrangements offer examples for procurement and partner-selection decisions.AI drug discovery draws doubts as venture bets yield little and most drugs still failWhen investing in AI, companies should ask platform vendors for evidence measured in clinical success rates.AI drug discovery: benchmark flaws may distort leaderboards, as CIOMS issues pharmacovigilance validation standardsVendor claims based on benchmarks should be verified independently; a validation standard is now available for pharmacovigilance AI.Faro raises $37 million to speed up clinical trials with AIAI built into protocol design and patient recruitment can cut the time and cost of trials.FDA updates cover substantial evidence, gene therapy and AI-enabled early-phase clinical trialsThe FDA's position on the use of AI in early-phase trials should be taken into account in development plans.Cluj research: where AI stands in drug discoveryThere is a gap between AI promises and real results; projects need realistic expectations.AI drug discovery: Nvidia backing, Novo Nordisk–AWS partnership and Insilico resultsLarge companies, cloud providers and AI startups are dividing up the work; partnership strategy must be aligned with this.SandboxAQ launches AI tool to cut cost of early-stage drug discoveryA new AI tool is available for early-stage research.Bristol Myers Squibb partners with Chai Discovery on AI antibody designLarge companies increasingly rely on external AI biotech partners for antibody design.Filament Health signs letter of intent with Darmiyan to explore BrainSee AI in early Alzheimer's trial designAn authorized AI tool could also play a role in selecting patients for trials.Tufts–Medable: AI agents could deliver $21m net benefit per programme in clinical trialsFor the business case, the figure should be recalculated for the company's own programme structure.TCS launches agentic AI platform for drug development and clinical trialsAgentic automation options should be mapped with trial sponsors and CRO partners.Clinical evidence for AI drug discovery remains 'disappointingly limited' after a decadeFor AI-based projects, clinical-level metrics should be specified to justify the investment.Novo Nordisk–AWS partnership and Takeda bet add to AI drug discovery investmentCloud AI partnerships point to faster research and outsourced infrastructure.MRC-funded £20m Cambridge hub to use AI to develop new medicinesThe academic AI hub could offer opportunities for collaboration.Evaxion adds AI-designed off-the-shelf glioblastoma vaccine EVX-05 to pipeline, drops EVX-03The company is focusing on AI-designed candidates, and the pipeline reshuffle is a signal to the market.STADA Health Report 2026: Hungarians more open to AI than the European averagePublic use of AI justifies a rethink of patient communication channels.Tufts CSDD: AI agents can deliver up to $21 million net value and 82x ROI per drug development programmeThe figures offer a benchmark for a business case when procuring AI agents for clinical trials, but they should be checked against a company's own programme data.AI-designed universal coronavirus vaccine tested in humans, reported safe and effectiveHuman data on the AI-designed vaccine strengthens validation of AI-based vaccine design.Novo Nordisk picks AWS as strategic partner for AI drug discovery; London hub to openThe partnership between a major drugmaker and a cloud provider is a benchmark: companies should assess how ready their own discovery data and computing capacity are for a similar collaboration.Aureka raises $100M Series B for AI drug discovery; Isomorphic Labs reportedly secures $2.1 billionCapital flowing to AI-native biotechs increases partnership and competitive pressure.Evotec and Almirall sign AI drug discovery deals as tech capital pushes fail-fast developmentThe contract and milestone terms of AI-biotech partnerships should also be weighed against the expectations of tech investors.Insilico Medicine nominates AI-designed ISM9077 for eye diseases, partners with THPharma on THP-001Insilico's case illustrates a strategy that uses AI from target nomination through to rethinking assets at phase 3.AI drug discovery under scrutiny as AI-designed drugs enter human trialsNews of AI discoveries should be measured against clinical results.Stanford researchers design 16 new viruses with AI, raising biosecurity concernsA new tool may emerge for research on drug-resistant pathogens, under strict biosafety conditions.Schrödinger and Bristol Myers Squibb sign deal on agentic AI drug discoveryA large drugmaker is deploying an agentic research tool as contracted software, which raises the question of rethinking internal research workflows.Generative biology is rewriting the rules of drug discovery, analysis saysGenerative models are becoming part of research strategy, so skills and data should be planned ahead of time.Hassabis steps back from DeepMind to focus on Isomorphic LabsOne of the flagship AI drug-discovery ventures is getting leadership attention, which could affect partnership talks.Recursion works with Genentech on first validated neuro target found through its AI mapValidation of a target found through the AI map and the scale of the partnership gauge how mature platform-based target discovery has become.QuantHealth raises $45 million to run AI simulations of clinical trialsIn the trial-design phase, simulation tools can screen out designs prone to failure before patients are enrolled.AI-designed drugs advance in trials with no US approval yet; proof is the bottleneckResearch time savings do not automatically convert into a regulatory advantage, so clinical development plans need separate reinforcement.Deep Intelligent Pharma launches AI CRO 6.0 for clinical trial workflowsCRO services are being extended with AI, which affects the selection criteria for outsourced trial management.H1 and Novo Nordisk partner on AI-driven clinical developmentThe data-platform partnership may also offer a model for AI support in investigator and site selection.Phylo and Chugai partner on AI agents for drug discoveryAgentic AI tools are appearing in research workflows with another major partner.Insilico Medicine gets China IND approval for AI-discovered Parkinson's drug candidate, launches benchmarkAn AI-designed candidate entering human clinical trials, along with a model benchmark, also offers a reference point for evaluating research tools.GSK to pay Relation Therapeutics up to $110 million for AI data and modelsLicensing AI models and datasets is becoming a separate procurement channel for expanding the research portfolio.